Top Page
Cibus
(NASDAQ:CBUS)
Cibus (CBUS) vs. SPDR S&P 500 ETF (SPY)
Cibus Business Overview & Revenue Model
Cibus Earnings Call Summary
Cibus Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 4.26M | 1.82M | 157.00K | 25.99M | 23.85M |
| Gross Profit | 4.26M | 1.42M | -1.38M | -2.57M | -11.28M |
| EBITDA | -241.63M | -314.58M | -15.21M | -25.43M | -41.53M |
| Net Income | -251.39M | -267.63M | -16.89M | -29.20M | -44.84M |
Balance Sheet | |||||
| Total Assets | 350.07M | 544.41M | 22.42M | 37.19M | 63.33M |
| Cash, Cash Equivalents and Short-Term Investments | 14.43M | 32.70M | 3.43M | 13.82M | 29.00M |
| Total Debt | 36.29M | 24.62M | 13.54M | 17.88M | 19.76M |
| Total Liabilities | 252.24M | 206.12M | 15.19M | 23.06M | 26.45M |
| Stockholders Equity | 92.16M | 293.47M | 7.23M | 14.13M | 36.88M |
Cash Flow | |||||
| Free Cash Flow | -58.85M | -50.53M | -20.88M | -19.31M | -45.46M |
| Operating Cash Flow | -58.04M | -46.21M | -19.36M | -18.81M | -43.67M |
| Investing Cash Flow | -808.00K | 55.06M | -1.52M | 11.20M | -13.48M |
| Financing Cash Flow | 40.60M | 20.32M | 9.99M | 3.74M | 15.41M |
Cibus Technical Analysis
Cibus Risk Analysis
Cibus Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $87.10M | ― | -31.93% | ― | -4.22% | 18.67% | |
54 Neutral | $72.22M | ― | 678.24% | ― | -69.59% | ― | |
52 Neutral | kr5.53B | 10.86 | -63.86% | 2.05% | 27.22% | 26.17% | |
51 Neutral | $53.65M | ― | -59.49% | ― | 21.15% | 46.44% | |
46 Neutral | $56.01M | ― | -290.21% | ― | -100.00% | 44.28% | |
44 Neutral | $86.17M | ― | -157.73% | ― | 104.78% | 40.41% | |
37 Underperform | $258.25M | ― | -141.69% | ― | ― | -17.06% |
Cibus Corporate Events
On July 21, 2025, Cibus, Inc. announced a reduction in workforce by approximately 34 full-time employees as part of its strategy to streamline business operations and focus on its most immediate and funded commercial opportunities. This move is expected to be completed by December 31, 2025, with the company incurring around $0.5 million in one-time charges for accrued vacation and severance payments in the third quarter of 2025, impacting affected employees who were informed on July 23, 2025.
The most recent analyst rating on (CBUS) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Cibus stock, see the CBUS Stock Forecast page.
On June 5, 2025, Cibus, Inc. entered into Securities Purchase Agreements with various investors, including its Board Chairman, as part of a public offering of 15,714,285 shares of Class A Common Stock. The offering, registered with the SEC, aims to raise funds for developing weed management traits in rice and other corporate purposes. The company has placed restrictions on stock transactions for 60 days post-offering. Additionally, Cibus engaged A.G.P./Alliance Global Partners as the sole placement agent, agreeing to a fee structure based on the proceeds from the sale of shares, with certain exclusions for the Board Chairman’s purchases.
The most recent analyst rating on (CBUS) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Cibus stock, see the CBUS Stock Forecast page.
Cibus, Inc. announced a strategic realignment to streamline operations, focusing on the commercial advancement of its weed management traits in rice and partner-funded sustainable ingredient programs. The company aims to reduce its annual net cash burn to $30 million by 2026 through cost-cutting measures, including rationalizing human capital and non-core facilities. Recent regulatory approvals in the U.S., Ecuador, and India support the company’s gene editing technologies, potentially enhancing its market positioning and facilitating future partnerships. Cibus plans to launch its rice traits commercially in Latin America by 2027-2028, with further expansion planned in the U.S. and Asia.
The most recent analyst rating on (CBUS) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Cibus stock, see the CBUS Stock Forecast page.
On May 22, 2025, Cibus, Inc.’s stockholders approved the adoption of the 2025 Employee Stock Purchase Plan (ESPP) during the company’s annual meeting. The plan, which was previously approved by the Board of Directors, includes the reservation of 326,384 shares of Class A common stock, with potential for annual increases. This approval marks a significant step in enhancing employee engagement and investment in the company, potentially impacting Cibus’s market position and stakeholder interests.
The most recent analyst rating on (CBUS) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Cibus stock, see the CBUS Stock Forecast page.
On May 22, 2025, Cibus, Inc. held its 2025 Annual Meeting of Stockholders where 64.94% of shares were represented. During the meeting, seven directors were elected, executive compensation was approved, BDO USA, P.C.’s appointment was ratified, and the 2025 Employee Stock Purchase Plan was approved. Additionally, the issuance and repricing of certain warrants, including those held by Rory Riggs, were approved, potentially leading to a change of control under Nasdaq rules.
The most recent analyst rating on (CBUS) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Cibus stock, see the CBUS Stock Forecast page.